Search clinical trials for: aldesleukin

Total 438 results

Southwest Oncology Group
National Cancer Institute (NCI); Eastern Cooperative Oncology Group; Children... and other collaborators

Completed

S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma

Melanoma (Skin)

United States, Australia
National Cancer Institute (NCI)

Completed

Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
Hoag Memorial Hospital Presbyterian

Completed

Biological Therapy in Treating Patients With Metastatic Cancer

Kidney Cancer | Unspecified Adult Solid Tumor, Protocol Specific | Melanoma (Skin)

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

Graft-Versus-Host Disease in Treating Patients With Recurrent or Refractory Lymphoma or Hodgkin's Disease

Lymphoma | Graft Versus Host Disease

United States
Sumithira Vasu

Completed

Decitabine, Donor Natural Killer Cells, and Aldesleukin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8... and other conditions

United States
Fred Hutchinson Cancer Center

Completed

Cellular Adoptive Immunotherapy in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndromes That Relapsed After Donor Stem Cell Transplant

Myelodysplastic Syndromes | Leukemia

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Biological Therapy After Chemotherapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Lymphoma | Leukemia

United States
National Cancer Institute (NCI)

Terminated

Interleukin-12 and Interleukin-2 in Treating Patients With Refractory or Recurrent Neuroblastoma

Recurrent Neuroblastoma

United States
National Cancer Institute (NCI)

Completed

Monoclonal Antibody Therapy With Sargramostim and Interleukin-2 in Treating Children With Neuroblastoma

Recurrent Neuroblastoma | Disseminated Neuroblastoma | Regional Neuroblastoma

United States
M.D. Anderson Cancer Center

Withdrawn

IPI-Biotherapy for Patients Previously Treated With Cytotoxic Drugs With Metastatic Melanoma

Melanoma
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Terminated

Gene-Modified Lymphocytes, High-Dose Aldesleukin, and Vaccine Therapy in Treating Patients With Progressive or Recurrent Metastatic Cancer

Kidney Cancer | Unspecified Adult Solid Tumor, Protocol Specific | Melanoma (Skin)

United States
Herbert Irving Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Comparison of Biological Therapies Following Combination Chemotherapy and Bone Marrow or Peripheral Stem Cell Transplantation in Women With Stage II or Stage III Breast Cancer

Breast Cancer

United States
National Institute of Allergy and Infectious Diseases...

Completed

Phase I Trial of the Combination of Zidovudine and Recombinant Interleukin-2 in Patients With Persistent Generalized Lymphadenopathy

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...
Applied Immunesciences

Completed

A Phase I Study of Autologous, Activated CD8(+) Lymphocytes Expanded In Vitro and Infused With or Without Recombinant Interleukin-2 to Patients With AIDS or Severe ARC

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Study of Zidovudine Plus Interleukin-2 in HIV-Infected Patients Who Have No Symptoms of Infection But Who Have Tender Lymph Nodes

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

The Safety and Effectiveness of Interleukin-2 Plus Zidovudine in Patients With AIDS or AIDS Related Complex

HIV Infections

United States
Leonard Appleman
Prometheus Laboratories

Completed

Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC)

Metastatic Renal Cell Carcinoma

United States
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Completed

Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
Roger Williams Medical Center

Withdrawn

Combination Chemotherapy Plus Biological Therapy in Treating Patients With Stage II or Stage III Breast Cancer

Breast Cancer

United States
Roswell Park Cancer Institute

Completed

High Dose Chemotherapy, Peripheral Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Acute Myeloid Leukemia

Leukemia

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Metastatic Melanoma

Stage IV Melanoma

United States
St. Jude Children's Research Hospital
National Cancer Institute (NCI); Assisi Foundation

Completed

Pilot Study of Expanded, Donor Natural Killer Cell Infusions for Refractory Non-B Lineage Hematologic Malignancies and Solid Tumors

Leukemia, Myeloid, Acute | Myelodysplastic Syndrome | T-cell Lymphoblastic Lymphoma | Leukemia, Lymphocytic, Acute, T-Cell | Juvenile Myelomonocytic Leukemia Lymphoblastic

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer

Brain and Central Nervous System Tumors

United States
National Cancer Institute (NCI)

Completed

Interleukin-12 Plus Interleukin-2 in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
University Health Network, Toronto
Merck Sharp & Dohme LLC

Completed

The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) Trial (ACTIVATE)

Advanced Ovarian Cancer | Malignant Melanoma

Canada
Masonic Cancer Center, University of Minnesota

Terminated

Chemotherapy, Total-Body Irradiation, Donor Natural Killer Cell Infusion, Aldesleukin, and UCB Transplant in Treating Patients With Relapsed or Refractory AML

Leukemia

United States
St. Luke's Medical Center

Completed

Indomethacin Plus Biological Therapy in Treating Patients With Advanced Melanoma

Melanoma (Skin)

United States
National Cancer Institute (NCI)

Terminated

Interleukin-12 and Interleukin-2 in Treating Patients With Mycosis Fungoides

Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma | Recurrent Mycosis Fungoides/Sezary Syndrome | Stage III Cutaneous T-cell Non-Hodgkin Lymphoma | Stage III Mycosis Fungoides/Sezary Syndrome | Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma | Stage IV Mycosis Fungoides/Sezary Syndrome | Stage I... and other conditions

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Combination Chemotherapy, Peripheral Stem Cell Transplantation, and Biological Therapy in Treating Patients With Solid Tumors or Lymphoma

Lymphoma | Unspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol Specific

United States
Loyola University
Chiron Corporation

Completed

Interleukin-2 in Treating Patients With Stage III or Stage IV Kidney Cancer

Kidney Cancer

United States
National Institute of Allergy and Infectious Diseases...
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Completed

Interleukin-2 Plus Anti-HIV Therapy in HIV-Infected Children With Weakened Immune Systems

HIV Infections

United States, Puerto Rico
Peking University People's Hospital

Unknown

Low-dose Interleukin-2 Treatment on Polymyalgia Rheumatica

Polymyalgia Rheumatica
Soma Jyonouchi
Baylor College of Medicine

Completed

Interleukin-2 Treatment for Wiskott-Aldrich Syndrome (WAS)

X-linked Thrombocytopenia | Wiskott-Aldrich Syndrome (WAS)

United States
Peking University People's Hospital

Unknown

Low-dose IL-2 ( Interleukin-2) Treatment in Macrophage Activation Syndrome（MAS）

Macrophage Activation Syndrome

China
Assistance Publique - Hôpitaux de Paris
Chiron Corporation

Unknown

Treating Patients With Childhood Acute Myeloid Leukemia With Interleukin-2 (Elam02)

Leukemia

France
Beth Israel Deaconess Medical Center

Completed

Efficacy of Low Dose, SubQ Interleukin-2 (IL-2) to Expand Endogenous Regulatory T-Cells in Liver Transplant Recipients

Liver Transplantation

United States
Dana-Farber Cancer Institute

Completed

Study of Individual Adult and Pediatric Patient Dose-escalated Interleukin-2 Therapy for Refractory Chronic GVHD

Chronic Versus Graft Host Disease

United States
Peking University People's Hospital

Unknown

Low-dose Interleukin-2 Treatment on Idiopathic Inflammatory Myopathy

Inflammatory Myopathy
Eli Lilly and Company

Completed

A Study of Flexible or Fixed Dose LY2216684 as Adjunctive Treatment for Participants With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment

Major Depressive Disorder (MDD)

United States, Puerto Rico, Finland, Japan, Slovakia, Czechia, Croatia
University Hospital, Bordeaux

Completed

Evaluating the Interest of Interleukine-2 for Patients With Active Warm Hemolytic Anemia Resistant to Conventional Treatment (ANEMIL)

Autoimmune Hemolytic Anemia

France
CINJRegulatory
National Cancer Institute (NCI); Rutgers Cancer Institute of New Jersey

Terminated

High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery

Recurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma

United States
National Cancer Institute (NCI)

Terminated

Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced Melanoma

Skin Cancer | Metastatic Melanoma

United States
National Cancer Institute (NCI)

Terminated

Gene Therapy Using Anti-Her-2 Cells to Treat Metastatic Cancer

Metastatic Cancer

United States
National Cancer Institute (NCI)

Terminated

Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Anti-gp100:154-162 TCR Gene Engineered Lymphocytes

Melanoma | Skin Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute

Active, not recruiting

Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma

Metastatic Melanoma

United States
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Completed

Cyclophosphamide and Fludarabine Followed By Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma

Recurrent Melanoma | Stage IV Melanoma | Stage III Melanoma

United States
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Completed

Cyclophosphamide and Fludarabine Followed by Vaccine Therapy, Gene-Modified White Blood Cell Infusions, and Aldesleukin in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
European Organisation for Research and Treatment...
Gruppo Italiano Malattie EMatologiche dell'Adulto

Unknown

Combination Chemotherapy, Interleukin-2, and Peripheral Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia

Leukemia
ImCheck Therapeutics
ILife Consulting; Exystat

Recruiting

Phase 1/2a Study of ICT01 Plus Low Dose SC IL-2 in Patients With Advanced Solid Tumors (EVICTION-2)

Solid Tumor, Adult

France

Search clinical trials for: aldesleukin

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Arab Emirates

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations